Tjoapack receives investment from Ampersand Capital Partners

Global contract packaging organisation (CPO), Tjoapack, has announced a €10m+ investment into its packaging and supply chain facility in Etten-Leur, Netherlands over the next two years.

At Tjoapack we're dedicated to shaping the future of the pharmaceutical supply chain which is why we're delighted to announce that over the next two years we'll be expanding our facility in Etten-Leur from 8,400sq.m. to 11,500 sq.m.

The investment of over €10m will more than double our primary packaging capacity for oral solids, as well as bolster our warehousing and cold chain capabilities to meet demand for our value-added logistics services.

Read more here

Global contract packaging organisation (CPO), Tjoapack is investing in its automated packaging capabilities to meet growing customer demand for pre-filled syringes and vials.

At Tjoapack we’re committed to ensuring we consistently bolster our offering and deliver the efficient and flexible services that our clients expect.

That is why we are excited to announce our most recent investment into our automated injectables packaging capabilities which will begin operations in 2021!

Learn more about our current syringe and vial packaging offerings here

Tjoapack Netherlands B.V., a global contract packaging organisation (CPO) for the pharmaceutical industry, today announced a majority investment from Ampersand Capital Partners, a private equity firm that specializes in partnering with entrepreneur-led healthcare companies.  Ampersand’s investment will be used to expand Tjoapack’s capabilities to meet growing industry demand for high quality pharmaceutical packaging services across different dosage forms.

The CPO has immediate plans to expand its automated packaging capabilities, including for injectable products.

Challenge us...

Secure data sharing across the pharmaceutical industry.

Postponement packaging is the practice of keeping products in a semi-finished, market agnostic state, and only finalising them when there is a specific market demand.

Used strategically, it will allow pharmaceutical manufacturers to respond to market-related fluctuation as well as variations in packaging requirements. In addition, postponement will enable pharma companies to lower working capital by reducing finished goods inventories, avoid repackaging work, reduce waste across the supply chain, and shorten their return on investment cycle.

In this whitepaper, Dr Anita Paz, Innovation Consultant and Dexter Tjoa, CEO (formerly Director Corporate Strategy) at Tjoapack, outline the postponement packaging principle and the key points to consider before implementing it as a supply chain strategy. They also discuss how this approach can be applied to different product portfolios and the benefits that adoption could bring to the pharmaceutical industry.

For more information on postponement packaging visit

With only 6 months left in which to become EU FMD-compliant, how can companies make the best use of their now limited options?

Tjoapack to perform the secondary packaging and assembly of product kits for supply to 25 European countries, the US, Canada and Australia.

Postponement printing is presenting interesting benefits for the pharmaceutical supply chain.